Comparison of ketoconazole and fluconazole as cytochrome P450 inhibitors: Use of steady-state infusion approach to achieve plasma concentration-response relationships

Drug Metabolism and Disposition

Volumn 24, Issue 2, 1996, Pages 211-215

  Ervine, Christopher M ^a   Matthew, Diane E ^a   Brennan, Beverley ^a   Houston, J Brian ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; CYTOCHROME P450; FLUCONAZOLE; KETOCONAZOLE; PHENAZONE;

ANIMAL EXPERIMENT; ARTICLE; BOLUS INJECTION; CONCENTRATION RESPONSE; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG HALF LIFE; DRUG INFUSION; DRUG METABOLISM; ENZYME INHIBITION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; STEADY STATE;

ANIMALS; ANTIFUNGAL AGENTS; ANTIPYRINE; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FLUCONAZOLE; INFUSION PUMPS; KETOCONAZOLE; LIVER; MALE; METABOLIC CLEARANCE RATE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0030063764     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. D. R. Kirsch, M. H. Lai, and J. O'Sullivan: Isolation of the gene for cytochrome P450LIA1 (lanosterol 14 α-demethylase) from Candida albicans. Gene 68, 229-237 (1988).
2. Y. Yoshida and Y. Aoyama: Interaction of azole fungicides with yeast cytochrome P45Q which catalyzes lanosterol 14α-demethylation. In "In Vitro and In Vivo Evaluation of Antifungal Agents" (K. Lawata and H. Van den Bossche, eds.), pp. 123-134. Elsevier, Amsterdam, 1986.
3. J. J. Sheets and J. I. Mason: Ketoconazole - a potent inhibitor of cytochrome P450 dependent drug metabolism in rat liver. Drug Metab. Dispos. 12, 603-606 (1984).
4. M. Pasanen, T. Taskinen, M. Iscon, E. A. Sonaniemi, M. Kairaluma, and O. Pelkonen: Inhibition of human hepatic and placental xenobiotic monooxygenases by imidazole antimycotics. Biochem. Pharmacol. 37, 3861-3866 (1988).
5. K. Lavrijsen, J. Van Houdt, D. Thijs, W. Meuldermans, and J. Heykants: Interaction of miconazole. ketoconazole and itraconazole with rat liver microsomes. Xenobiotica 17, 45-57 (1987).
6. C. G. Meredith, A. L: Maldonado, and K. V. Speeg: The effect of ketoconazole on hepatic oxidauve drug metabolism in the rat in vivo and in vitro. Drug Metab. Dispos. 13, 156-162 (1985).
7. I. Shuster: The interaction of representative members from two classes of antimycotics - the azoles and the allylamines - with cytochrome P450 in steroidogenic tissues and liver. Xenobiotica 15, 529-546 (1985).
8. J. B. Houston, M. J. Humphrey, D. E. Matthew, and M. H. Tarbit: Comparison of two azole antifungal drugs, ketoconazole and fluconazole, as modifiers of rat hepatic monooxygenase activity. Biochem. Pharmacol. 37, 401-408 (1988).
9. M. Maurice, L. Pichard, M. Doujat, I. Fabre, H. Joyeux, J. Domergue, and P. Maurel: Effects of imidazole derivatives on cytochromes P450 from human hepatocytes in primary culture. Fed. Am. Soc. Exp. Biol. J. 6, 752-758 (1992).
10. D. J. Back and J. F. Tjia: Comparative effects of antimycotic drugs ketoconazole, fluconazole, itraconazole and terbinafine on the metabolism of cyclosporin by human liver microsomes. Br. J. Clin. Pharmacol. 32, 624-626 (1991).
11. J. T. B. Shaw, M. H. Tarbit, and P. F. Troke: Cytochrome P450 mediated sterol synthesis and metabolism: differences in sensitivity to fluconazole and other azoles. In "Recent Trends in the Discovery, Development and Evaluation of Antifungal Agents" (R. A. Fromtling, ed.), pp. 125-139. J. R. Prous Science Publishers, Barcelona, 1987.
12. K. Richardson, K. W. Brammer, M. S. Marriott, and P. F. Troke: Activity of UK-49858, a bis-triazole derivative, against experimental infections with Candida albicans and Trichophyton mentagrophytes. Antimicrob. Agents Chemother. 27, 832-839 (1985).
13. P. F. Troke, R. J. Andrews, K. W. Brammer, M. S. Marriott, and K. Richardson: Efficacy of UK-49858 (fluconazole) against Candida albicans experimental infections in mice. Antimicrob. Agents Chemother. 28, 815-820 (1986).
14. I. La Delfa, Q. M. Zhu, Z. Mo, and T. F. Blaschke: Fluconazole is a potent inhibitor of antipyrine metabolism in vivo in mice. Drug Metab. Dispos. 17, 49-53 (1989).
15. K. Morita, H. Konishi, and H. Shimakawa: Fluconazole: a potent inhibitor of cytochrome P450-dependent drug metabolism in mice and human in vivo. Comparative study with ketoconazole. Chem. Pharm. Bull. 40, 1247-1251 (1992).
16. H. E. Poulsen, and S. Loft Antipyrine as a model drug to study hepatic drug-metabolizing capacity. Hepatology 6, 374-382 (1988).
17. B. K. Park, and N. R. Kitteringham: Relevance and means of assessing induction and inhibition of drug metabolism in man. Prog. Drug Metab. 11, 1-55 (1989).
18. C. M. Ervine and J. B. Houston: Disposition of azole antifungal agents. III. Binding of fluconazole and other azoles in rat liver. Pharm. Res. 11, 961-965 (1994).
19. M. J. Humphrey, S. Jevons, and M. H. Tarbit: Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug in animals and humans. Antimicrob. Agents Chemother. 28, 648-653 (1985).
20. R. P. Remmel, K. Amoh, and M. M. Abdel-Monem: The disposition and pharmacokinetics of ketoconazole in the rat. Drag Metab. Dispos. 15, 735-739 (1987).
21. D. Matthew, B. Brennan, K. Zomorodi, and J. B. Houston: Disposition of azole antifungal agents. I. Nonlinearities in ketoconazole clearance and binding in rat liver. Pharm. Res. 10, 418-422 (1993).
22. A. Adedoyin, L. Aarons, and J. B. Houston: Plasma concentration-response relationship for cimetidine inhibition of drug metabolism in the rat. Drug Metab. Dispos. 15, 127-132 (1987).
23. P. G. Harms, and S. R. Ojeda: A rapid and simple procedure for chronic cannulation of the rat jugular vein. J. Appl. Physiol 36, 391-391 (1974).
24. D. E. Matthew, and J. B. Houston: Drug metabolizing capacity in vitro and in vivo. I. Correlations between hepatic microsomal monooxygenase markers in β-naphthoflavone-induced rats. Biochem. Pharmacol. 40, 743-749 (1990).
25. P. N. Shaw, and J. B. Houston: Kinetics of drug metabolism inhibition: use of metabolite concentration-time profiles. J. Pharmacokinet. Biopharm, 15, 497-510 (1987).
26. G. C. Kahn, A. R. Boobis, S. Murray, and D. S. Davies: Differential effects of 3-methylcholanthrene and phenobarbitone treatment on the oxidative metabolism of antipyrine in vitro by microsomal fractions of rat liver. Xenobiotica 12, 509-516 (1982).
27. S. Loft and H. E. Poulsen: Metabolism of metronidazole and antipyrine in isolated rat hepatocytes. Influence of sex and enzyme induction and inhibition. Biochem. Pharmacol. 38, 1125-1136 (1989).
28. S. A. Ballard, A. Lodola, and M. H. Tarbit: A comparative study of 1-substituted imidazole and 1,2,4-triazole antifungal compounds as inhibitors of testosterone hydroxylations catalysed by mouse hepatic microsomal cytochromes P450. Biochem. Pharmacol. 37, 4643-4651 (1988).
29. H. L. Bomont, M. H. Tarbit, M. J. Humphrey, and J. B. Houston: Disposition of azole antifungal agents. II. Hepatic binding and clearance of the probe compound DTP. Pharm. Res. 11, 951-960 (1994).
30. J. R. Gillette: Techniques for studying drug metabolism in vitro. In "Fundamentals of Drug Metabolism and Drug Disposition" (B. N. LaDu, H. G. Mandel, and E. L. Way, eds.), pp. 400-418. Williams & Wilkins, Baltimore, 1971.
31. P. N. Shaw, J. Tseti, S. Warburton, A. Adedoyin, and J. B. Houston: Inhibition of antipyrine metabolite formation: steady state studies with cimetidine and metyrapone in rats. Drug Metab. Dispos. 14, 271-276 (1986).
32. J. Rhodes, S. T. Hall, and J. B. Houston: Inhibition of antipyrine metabolite formation in rats in vivo. Xenobiotica 14, 677-686 (1984).